Altered heterochromatin organization after perinatal exposure to zidovudine

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 179-187

  Senda, Sho ^a,b   Blanche, Stéphane ^b,c   Costagliola, Dominique ^a,d   Cibert, Christian ^e   Nigon, Fabienne ^a,b   Firtion, Ghilaine ^f   Floch, Corinne ^g   Parat, Sophie ^c   Viegas Péquignot, Evani ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CNRS   (France)

^f Université Paris Diderot Paris7 ^*  (France)

^g HÔPITAL LOUIS MOURIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CHROMATIN; DISEASE TRANSMISSION; DNA METHYLATION; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAUTERINE GROWTH RETARDATION; LEUKOCYTE; PREGNANCY; PRIORITY JOURNAL;

ADOLESCENT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 16; COHORT STUDIES; DNA METHYLATION; FEMALE; HETEROCHROMATIN; HIV INFECTIONS; HIV-1; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; LEUKOCYTES; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; ZIDOVUDINE;

EID: 34147152291     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
2. Scotland GS, van Teijlingen ER, van der Pol M, Smith WC. A review of studies assessing the costs and consequences of interventions to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 2003; 17:1045-1052.
3. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986; 83:8333-8337.
4. Vazquez-Padua MA, Starnes MC, Cheng YC. Incorporation of 3′-azido-3′-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun 1990; 2:55-62.
5. Lewis W. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antivir Res 2003; 58:189-197.
6. Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues - a survey. Antivir Res 2001; 49:55-74.
7. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997; 89:1602-1608.
8. Olivero OA, Shearer GM, Chougnet CA, et al. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS 1999; 13:919-925.
9. Gerschenson M, Nguyen V, Ewings EL, et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004; 20:91-100.
10. Walker DM, Poirier MC, Campen MJ, et al. Persistence of mitochondrial toxicity in hearts of female B6C3F1 mice exposed in utero to 3′-azido-3′-deoxythymidine. Cardiovasc Toxicol 2004; 4:133-153.
11. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089.
12. Cooper E, DiMauro S, Sullivan M, et al. Biopsy-confirmed mitochondrial dysfunction in an HIV-exposed infant whose mother received combination antiretrovirals during the last 6 weeks of pregnancy. XV International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract TuPeB4394.
13. Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 2002; 29:323-329.
14. Poirier MC, Divi RL, Al-Harthi L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33:175-183.
15. Ayers KM, Torrey CE, Reynolds DJ. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol 1997; 38:195-198.
16. Diwan BA, Riggs CW, Logsdon D, et al. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice. Toxicol Appl Pharmacol 1999; 161:82-99.
17. National Toxicology Program. Technical Report on the Toxicology and carcinogenesis studies of transplacental AZT (CAS No. 30516-87-1) in Swiss (CD-1) mice (in utero studies). NTP TR 522, NIH Publication No. 06-4458, 2006.
18. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:463-467.
19. Brogly S, Williams P, Seage GR, 3rd, Van Dyke R. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts. J Acquir Immune Defic Syndr 2006; 41:535-536.
20. Parra I, Flores C, Adrian D, Windle B. AZT induces high frequency, rapid amplification of centromeric DNA. Cytogenet Cell Genet 1997; 76:128-133.
21. Richards EJ, Elgin SC. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 2002; 108:489-500.
22. Grewal SI, Moazed D. Heterochromatin and epigenetic control of gene expression. Science 2003; 301:798-802.
23. Bombali V, Moggs JG, Orphanides G. Perturbation of epigenetic status by toxicants. Toxicol Lett 2004; 149:51-58.
24. Moggs JG, Goodman JI, Trosko JE, Roberts RA. Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol 2004; 196:422-430.
25. Moorhead PS, Noweli PC, Mellman WJ, et al. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res 1960; 20:613-616
26. Jiang YL, Rigolet M, Bourc'his D, et al. DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. Hum Mutat 2005; 25:56-63.
27. Isogai Y, Tjian R. Targeting genes and transcription factors to segregated nuclear compartments. Curr Opin Cell Biol 2003; 15:296-303.
28. McNairn AJ, Gilbert DM. Epigenomic replication: linking epigenetics to DNA replication. Bioessays 2003; 25:647-656.
29. Adams RR, Wheatley SP, Gouldsworthy AM, et al. INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow. Curr Biol 2000; 10:1075-1078.
30. Csink AK, Henikoff S. Something from nothing: the evolution and utility of satellite repeats. Trends Genet 1998; 14:200-204.
31. Xu GL, Bestor TH, Bourc'his D, et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999; 402:187-191.
32. Narayan A, Ji W, Zhang XY, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998; 77:833-838.
33. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 1994; 91:11797-11801.
34. Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycyridine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005; 25:4727-4741.
35. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-428.
36. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457-463.
37. Blanco-Betancourt CE, Moncla A, Milili M, et al. Defective B-cell-negative selection and terminal differentiation in the ICF syndrome. Blood 2004; 103:2683-2690.
38. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053-2061.
39. European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers. AIDS 2004; 18:2009-2017.
40. Smale ST. The establishment and maintenance of lymphocyte identity through gene silencing. Nat Immunol 2003; 4:607-615.
41. Alcobia I, Dilao R, Parreira L. Spatial associations of centromeres in the nuclei of hematopoietic cells: evidence for cell-type-specific organizational patterns. Blood 2000; 95:1608-1615.
42. Alcobia I, Quina AS, Neves H, Clode N, Parreira L. The spatial organization of centromeric heterochromatin during normal human lymphopoiesis: evidence for ontogenically determined spatial patterns. Exp Cell Res 2003; 290:358-369.
43. Brown KE, Baxter J, Graf D, Merkenschlager M, Fisher AG. Dynamic repositioning of genes in the nucleus of lymphocytes preparing for cell division. Mol Cell 1999; 3:207-217.
44. Ansel KM, Lee DU, Rao A. An epigenetic view of helper T-cell differentiation. Nat Immunol 2003; 4:616-623.
45. Su RC, Brown KE, Saaber S, et al. Dynamic assembly of silent chromatin during thymocyte maturation. Nat Genet 2004: 36:502-506.